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Projected increase in amyotrophic lateral sclerosis
from 2015 to 2040
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Although amyotrophic lateral sclerosis (ALS) is relatively rare, the socioeconomic significance
of the disease is extensive. It is therefore vital to project the epidemiologic trend of ALS.
To date, there have been few published studies attempting to estimate the number and
distribution of ALS cases in the upcoming years. Here we show that the number of ALS cases
across the globe will increase from 222,801 in 2015 to 376,674 in 2040, representing an
increase of 69%. This increase is predominantly due to ageing of the population, particularly
among developing nations. This projection is likely an underestimate due to improving
healthcare and economic conditions. The results should be used to inform healthcare policy
to more efficiently allocate healthcare resources.
DOI: 10.1038/ncomms12408 OPEN
1 Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland
20892, USA. 2 The Commonwealth Medical College, Scranton, Pennsylvania 18509, USA. 3 ’Rita Levi Montalcini’ Department of Neuroscience, University of
Torino, Turin 10124, Italy. 4 Neuroscience Institute of Torino, Turin 10124, Italy. 5 Statistical Genetics Group, Laboratory of Neurogenetics, National Institute on
Aging, National Institutes of Health, Bethesda, Maryland 20892, USA. 6 Neurodegenerative Diseases Research Unit, Laboratory of Neurogenetics, National
Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA. 7 Brain Science Institute, Department of
Neurology, Johns Hopkins University, Baltimore, Maryland 21205, USA. Correspondence and requests for materials should be addressed to B.J.T.
(email: traynorb@mail.nih.gov).
NATURE COMMUNICATIONS | 7:12408 |DOI: 10.1038/ncomms12408 |www.nature.com/naturecommunications 1
A
ccording to the United Nations, the number of individuals
in the world above age 60 is expected to increase rapidly.
This ageing pattern is especially significant in developing
countries, where the proportion of older individuals will
increase from about 9% in 2015 to 16% by 2040 (ref. 1). The
number of individuals diagnosed with chronic disease has grown
due to this trend2. For instance, one study found that the number
of individuals with Parkinson’s disease will double between 2005
and 2030, and the weight of disease will shift from developed
nations to developing nations3. While similar studies have been
conducted on other diseases4,5, no such study has sought to
project the number of amyotrophic lateral sclerosis (ALS) cases.
ALS is the most common adult-onset motor neuron disease.
It is characterized by both upper and lower motor neuron
degeneration and has a median survival of 2–4 years6. The
worldwide annual incidence of ALS is about 1.9 per 100,000
(ref. 7), with uniform rates in Caucasian populations and lower
rates in African, Asian and Hispanic populations8. Although rare,
the socioeconomic significance of the disease is substantial9,10.
Accurate projections of ALS case numbers will help guide
healthcare policy and the effective allocation of resources.
The objective of our study is to estimate the number of
individuals with ALS across the globe in the years 2015 and 2040.
To do this, we use previously published data on the incidence of
ALS. We show that the number of cases of this fatal
neurodegenerative disease will increase by 69% over the next 25
years and that this increase is primarily due to population ageing.
We further demonstrate an overall shift in the projected number
of ALS cases away from developed countries towards more
developing nations.
Results
Population and ALS prevalence estimates. We identified ALS
incidence studies for 10 countries and geographical regions
(China, Europe, Iran, Japan, Libya, New Zealand, Serbia, Taiwan,
the United States and Uruguay) that were suitable for analysis.
The total population of these countries in 2015 was 2.46 billion,
representing 34% of the world population. The total population of
the countries above age 20 will increase by 7.7% from 1.89 billion
in 2015 to 2.03 billion in 2040.
The prevalence rates of ALS were highest in Uruguay, New
Zealand and the United States, and lowest in Serbia, China and
Taiwan (Supplementary Tables 1 and 2). The age groups with the
highest prevalence rates of ALS were from age 60 to 79.
Estimates of ALS case numbers in 10 regions. In 2015, there
were 45,810 men and 34,352 women diagnosed with ALS in the
10 regions for which incidence rates were available. The projected
number of individuals with ALS in 2040 was 60,394 men and
45,299 women. Thus, the total number of individuals with ALS is
expected to grow from 80,162 in 2015 to 105,693 in 2040,
representing an increase of 431% (Table 1). The geographical
distribution of this increase in case numbers is shown in Fig. 1.
The number of ALS cases will increase substantially in the
developing world over the next 25 years (Fig. 2). Notably,
developing countries (China, Iran, Libya, Serbia, Taiwan and
Uruguay) will see a 50% increase in the number of ALS cases
from 2015 to 2040. In contrast, cases in developed countries
(Europe, Japan, New Zealand and the United States) will increase
by only 24% during the same time period. The net result of this
pattern is that the weight of disease will gradually shift from
developed countries to developing countries. For instance, in
2015, the developed countries studied accounted for 71% of ALS
cases, but this will drop to 67% by 2040. This trend is most
notable in Iran and Libya, where the number of individuals with
ALS in each country will more than double over this time period.
Estimate of global ALS case numbers. To estimate the
number of cases across the world, incidence rates obtained
from countries were applied to the population of each
Table 1 | Projected number of ALS cases classified by country and year.
Country 2015 2040
Male Female Male Female
Africa
Libya 198 95 433 202
Americas
United States 12,656 9,179 17,184 12,122
Uruguay 146 61 193 76
Asia
China 12,261 8,068 17,281 12,453
Iran 774 635 1,699 1,293
Japan 3,241 2,625 3,558 2,873
Taiwan 345 277 432 364
Europe
EU 28* 15,960 13,248 19,320 15,704
Serbia 74 52 69 48
Oceania
New Zealand 154 111 226 165
Total by sex 45,810 34,352 60,394 45,299
Overall total
No. of cases/total population 80,162/1.89 billion 105,693/2.04 billion
*EU28, European Union region consisting of 28 countries including Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland,
Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom.
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country’s respective continent. Incidence rates for the United
States were used for North America, Uruguay for South America,
Libya for Africa and New Zealand for Oceania. Incidence
rates from China, Japan, Taiwan and Iran were weighted
according to the size of the study population and applied to
Asia. European cases were estimated using incidence rates
from the European pooled analysis. By our estimates, the
number of cases of ALS in the world will increase from 222,801 in
2015 to 376,674 in 2040, representing an increase of 69%.
The largest increase will be seen in Africa with 116%, followed
by Asia with 81% and South America with 73%. Meanwhile,
the population over the age of 20 in these regions will increase by
only 33% over the same time period.
Discussion
The number of individuals with ALS in the 10 studied countries
and regions is expected to increase by nearly one third from
80,162 in 2015 to 105,693 in 2040. A growing population size
cannot solely explain this increase. While the number of
individuals over the age of 20 living in these countries will
increase by only 7.7%, the number of individuals with ALS will
increase by 31%. Instead, the observed expansion in ALS cases is
most likely due to ageing of the populations of these countries
that leads to an increase in the number of individuals in the age
groups most at risk of developing ALS (60–79 years of age)1.
Population ageing may also explain our projection that the
weight of ALS will shift from developed countries to developing
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Figure 1 | Projected increase in the number of individuals with ALS from 2015 to 2040. The countries studied are shown in light blue. The bars represent
the growth in number of cases from 2015 (royal blue) to 2040 (navy). The per cent increase in cases during this time is shown under the country’s name.
The map was created in R using the packages maps, ggplot2 and ggsubplot (available at https://cran.r-project.org/).
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Figure 2 | Projected increase in the number of individuals with ALS in developed and developing countries from 2015 to 2040. The bar graph
on the left shows the increase in cases in developed (green) and developing (blue) countries from 2015 to 2040. The graph on the right shows
the projected number of cases in each country in 2040. The graph was created in R using the packages ggplot2 and ggsubplot (available at
https://cran.r-project.org/).
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countries. The adult population in developing countries will
increase by only 7.6%, but the number of ALS cases will
increase by over 50%. This is most likely due to the rapid
ageing of these populations (Fig. 3)1. A recent review indicates
that the standardized total annual cost per patient with ALS was
$69,475 in the United States, $59,018 in Spain, $47,092 in
Germany, $21,732 in the Netherlands and $11,251 in Greece11.
There are currently no studies outlining the cost of ALS
in developing countries, and while economic costs are
most likely lower in these locations, the increase in ALS cases
will place an immense burden on their healthcare systems in the
coming decades.
The data for ALS are similar to the projected trend of
Parkinson’s disease where the number of individuals with this
form of neurodegenerative disease will double between 2005
and 2030 (ref. 3). Furthermore, the weight of ALS will continue
to shift towards the developing world, a trend also expected
with Parkinson’s disease. These data mirror the prediction
that chronic disease will increase in the coming years due to
ageing of the population2.
There are several limitations to this study. First, our global
estimation that the number of individuals with ALS will increase
by more than two thirds is likely conservative. While studies show
that incidence rates of ALS tend to remain constant7, our
projections assume that disease prevalence will also remain
constant. However, survival of individuals with ALS will improve
as healthcare and economic conditions continue to improve,
particularly in developing countries. In addition, while incidence
rates over age 80 tend to fall, it is not clear whether this decrease is
due to a lower risk of developing ALS in the elderly12. It is
therefore possible that incidence rates in the elderly are higher than
reported, again making the results of this study an underestimate.
Second, our case number calculations rely on published data of
country-specific estimates of ALS incidence. While this approach
can identify important geographical differences in incidence rates,
it also introduces variation due to methodological differences
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Figure 3 | Population growth of the studied countries from 2015 to 2040. The population pyramids show the growth and ageing trends of the
populations in the studied countries. Females are located on the right (navy blue) and males on the left (royal blue). The line graph shows a positive
correlation between the per cent increase in ALS cases and the per cent increase in median population age from 2015 to 2040 (ref. 37). The graph
was created in R using the package ggplot2 (available at https://cran.r-project.org/).
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between studies. For example, two studies defined their patient
population as those with motor neuron disease rather than ALS
(China and Libya)13,14. Although the majority of motor neuron
disease cases are ALS, the incidence rates reported from these
studies may be overestimates due to possible inclusion of
non-ALS cases. Additionally, one study was published before
the El Escorial criteria14, and so the cases included in that study
may not have been diagnosed accurately. Finally, population-
based longitudinal studies are the gold standard for estimating
ALS case numbers within a country15, but this enhanced type of
study was not available for all geographical regions, most notably
in Africa, perhaps leading to an underestimate of the global ALS
case numbers.
Our projected number of ALS cases should not be taken as an
estimate of the global burden of this neurodegenerative disease.
The World Health Organization (WHO) defines the burden of
disease as years of life lost due to both premature mortality and
time lived in states of less than full health16. Our study, on the
other hand, sought only to calculate the number of individuals
throughout the world living with ALS and not to assess their
burden of disease. Nevertheless, we maintain that this is a useful
addition to the field, as the global burden of ALS has not yet been
studied by WHO17.
A major strength of this study is that an R code was used to
systematically download data from the United States
Census International Data Base and calculate the projected
number of cases. This code is both reproducible and flexible,
and can be used by other researchers to quickly acquire
population data and apply it to other diseases. We argue that
this type of reproducibility should become the standard in
scientific literature18,19.
In conclusion, the number of individuals with ALS will grow
significantly between 2015 and 2040. Furthermore, the weight of
disease will shift away from the developed world towards
developing countries. Our projection fills a sizeable gap in the
scientific literature. Understanding these trends is important to
inform healthcare policy and more efficiently allocate local
healthcare resources.
Methods
Literature search. Age- and sex-specific incidence rates were ascertained from
published studies. MEDLINE (via PubMed) was searched for English-language
articles published after January 1995, when the El Escorial criteria for diagnosis of
ALS were implemented20. The MeSH terms ‘amyotrophic lateral sclerosis’ or
‘motor neuron disease’ along with ‘incidence,’ ‘prevalence,’ or ‘epidemiology’
were used to identify articles. The search was supplemented by examining the
reference sections of the retrieved publications. Only articles reporting quantitative
incidence rates separated by age group and sex were selected. For countries
with multiple available studies, the most recent population-based, observational
study was selected.
The population structure of each country from 2015 to 2040 was obtained
from the United States Census Bureau International Programs International
Data Base21. Two recent reviews citing survival rates of ALS were used to
identify survival rates for each of the studied regions22,23.
Case number calculation. The number of ALS cases was estimated in each
country based on the product of (a) the age-specific and sex-specific incidence rates
for that particular country, (b) the age-specific and sex-specific population of that
country and (c) the median disease duration for that country24. This provided
comparable results to published prevalence data (see Chio` et al.7 for review).
To make this work reproducible, a computer code was written in R programming
to automatically obtain the data from the International Data Base website and then
to calculate the ALS case numbers for 2015 and 2040 (ref. 25).
To estimate the number of cases across the world, we applied the incidence and
survival rates obtained for each country to their respective continent. If more than
one study existed for a continent, the incidence and survival rates were weighted
according to the size of the population covered by the study.
Identified publications. The original search for incidence rates yielded 355
articles. A recent pooled analysis was selected to represent Europe (European
Union 28 countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic,
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy,
Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal,
Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom)26. A total of
eight other articles met the full criteria (China, Iran, Japan, New Zealand,
Serbia, Taiwan, the United States and Uruguay)13,27–33. The search criteria were
extended to include an earlier year of publication in order to identify incidence
rates for a country in Africa (Supplementary Table 3)14. When age ranges of the
studies did not match the age ranges of the International Data Base, the given
incidence rates were applied across multiple age groups. Seven articles were also
identified that gave survival rates for the studied regions6,14,27,29,34–36.
Data availability. Data that support the findings of this study were obtained from
the United States Census Bureau International Programs International Data Base,
which is a public domain resource available at https://www.census.gov/population/
international/data/idb/region.php. The R programming code used to analyse these
data is freely available at https://github.com/kca5031/ALSCases. All other relevant
data are available from the authors on request.
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